Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should complete the week 16 assessments in the double-blind study (TA-7284-11)~Exclusion Criteria:~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with serious renal or hepatic disease~* Patients who are the excessive alcohol addicts~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋insulin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).